PET imaging utilization and trends in Germany: a comprehensive survey.
설문조사
1/5 보강
[INTRODUCTION] PET imaging is a key diagnostic procedure in clinical routine worldwide.
APA
Holzgreve A, Hellwig D, et al. (2025). PET imaging utilization and trends in Germany: a comprehensive survey.. European journal of nuclear medicine and molecular imaging, 52(12), 4390-4398. https://doi.org/10.1007/s00259-025-07323-x
MLA
Holzgreve A, et al.. "PET imaging utilization and trends in Germany: a comprehensive survey.." European journal of nuclear medicine and molecular imaging, vol. 52, no. 12, 2025, pp. 4390-4398.
PMID
40317303 ↗
Abstract 한글 요약
[INTRODUCTION] PET imaging is a key diagnostic procedure in clinical routine worldwide. While public figures on PET volume are available in many countries, until now these numbers were not publicly known for Germany.
[METHODS] On behalf of the PET committee of the German Society of Nuclear Medicine, we conducted a comprehensive survey among PET centers in Germany to collect data on PET imaging, including the total PET volume and indication groups.
[RESULTS] National total PET volume in 2021 was 154,400 scans (94% PET/CT, 6% PET/MRI). PET volume in 2021 normalized to total population was lower in Germany (1,857 scans per 1 million inhabitants) when compared to public figures from France (10,182 scans), Belgium (9,866 scans), or Italy (4,312 scans). PET volume in Germany demonstrated significant growth 2017 to 2021 (+ 48%). Top three indication fields were oncological (re)staging (76%), theranostic (13%), and neurology (4%). The top three indications were lung cancer (31%), prostate cancer (16%), and lymphoma/leukemia (12%). The top three radiotracers used were [F]FDG (75%), PSMA radioligands (17%), and somatostatin-receptor radioligands (8%).
[CONCLUSIONS] Clinical adoption of PET imaging in Germany is behind compared to Italy, France, and Belgium. However, newly established outpatient reimbursement seems to contribute to recent growth in PET volume. We observe considerable shift towards theranostic applications.
[METHODS] On behalf of the PET committee of the German Society of Nuclear Medicine, we conducted a comprehensive survey among PET centers in Germany to collect data on PET imaging, including the total PET volume and indication groups.
[RESULTS] National total PET volume in 2021 was 154,400 scans (94% PET/CT, 6% PET/MRI). PET volume in 2021 normalized to total population was lower in Germany (1,857 scans per 1 million inhabitants) when compared to public figures from France (10,182 scans), Belgium (9,866 scans), or Italy (4,312 scans). PET volume in Germany demonstrated significant growth 2017 to 2021 (+ 48%). Top three indication fields were oncological (re)staging (76%), theranostic (13%), and neurology (4%). The top three indications were lung cancer (31%), prostate cancer (16%), and lymphoma/leukemia (12%). The top three radiotracers used were [F]FDG (75%), PSMA radioligands (17%), and somatostatin-receptor radioligands (8%).
[CONCLUSIONS] Clinical adoption of PET imaging in Germany is behind compared to Italy, France, and Belgium. However, newly established outpatient reimbursement seems to contribute to recent growth in PET volume. We observe considerable shift towards theranostic applications.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.